Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Expert Insights on Pharmaceutical Industry

The Pharmaceutical Industry is the business sector typically encompassing the production and use of small molecule drugs derived from chemical sources. These substances are aimed at treating, curing, preventing, or recognizing disease.

Gerson Lehrman Group Council Members are available to discuss Pharmaceutical Industry via phone consultations, live meetings, surveys, and other custom GLG products and services.

Find, engage, and manageSM experts today through the GLG platform

Featured Council Members

GLG Council Members are leading experts including academics, scientists, and industry specialists

Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

Kuldeepak Sharma, PhDWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

President/Pharmaceutical ConsultantDr. Kuldeepak Sharma

Gregory Glover, Partner, Pharmaceutical Law Group PC

Gregory GloverWhat is a GLG Educator?|GLG Educators have qualified for GLG Member Programs and are therefore eligible to participate in ongoing in-depth consulting projects with GLG clients.What is a Premium Council Partner?|Premium Council Partners are leading Professional Service Firms that work exclusively with GLG.

PartnerPharmaceutical Law Group PC

Mark Capriani, MBA, President and Chief Executive Officer, ACIES HEALTH INC

Mark Capriani, MBAWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

President and Chief Executive OfficerACIES HEALTH INC

Alexey Cherpakov, Marketing director, Raifarm

Alexey CherpakovWhat is a GLG Educator?|GLG Educators have qualified for GLG Member Programs and are therefore eligible to participate in ongoing in-depth consulting projects with GLG clients.What is a Premium Council Partner?|Premium Council Partners are leading Professional Service Firms that work exclusively with GLG.

Marketing directorRaifarm

Nailesh Bhatt, Managing Director, PROXIMARE INC

Nailesh BhattWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Managing DirectorPROXIMARE INC

Browse all 407 Leading Experts

Recent Live Meetings

Interactive roundtables, private visits, and small scale seminars are types of GLG Live Meetings

May 22, 2009 | Webcast

GLG Webcast: Consolidation Trends - China Pharma on May 22, 2009 at 7:30AM ET

Recent News Analyses

News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations

Sandoz’ Generic Drug Push in Japan: Good Timing; Interesting Challenges

October 7, 2009

Sandoz Plans to Sell More Drugs in Japan, May Acquire Companies | www.bloomberg.com

Novartis AG's generic pharmaceutical unit, Sandoz AG's timing for entry into the Japanese pharmaceutical market is excellent as seismic forces in the market make generic drugs more attractive than ever. Sandoz CEO Jeff George's challenges include a prestige-driven hospital system and a private practice/physician...

India is a good clinical trial destination with new CROs in future

September 27, 2009

Growing pharma market makes India a clinical trial destination: Report | www.thehindubusinessline.com

Pharmaceutical boom in India has opened up the doors of new clinical trials due to various factors, like new research & treatment avenues, which can be explored best in Indian Clinical Trials due to ease of carrying out Clinical trials in india, which is also giving birth to new CROs.

Electronic Health Record Data will be an Industry Gold Mine

October 2, 2009

Survey Highights Power, Limits of EHR Data | www.healthdatamanagement.com

The real value of getting everybody on an electronic medical record in the next decade will not be realized until the data produced through this transition become easily accessible and analyzable to identify, implement and continuously improve best practices. More than three quarters of 732 surveyed...

Browse all 7647 GLG News Analyses

Contact Gerson Lehrman Group to engage a Pharmaceutical Industry expert